← Leaderboards
Amaia Lujambio
Icahn School Of Medicine At Mount Sinai
$5,368,450
Attributed
$9,131,181
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,131,181 · 3
By mechanism
R01$6,408,889 · 2
R37$2,722,292 · 1
Top collaborators
- Arvin Dar6 shared
- Ernesto Guccione6 shared
- Satdarshan Singh Monga5 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Ernesto Guccione$11,143,318
- Margaret Sewell$2,654,814
- Eric E Schadt$18,256,361
- Panagiotis Roussos$45,081,240
- Josep M Llovet$2,681,666
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorMalignant Neoplasm Of LiverPrimary Carcinoma Of The Liver CellsFda ApprovedCtnnb1 GeneImmune Checkpoint InhibitorOncogenicMouse ModelBeta CateninPhenotypeBay 54-9085SamplingMutationProgrammed Cell Death Protein 1ResponseBiological MarkersPatient StratificationImmune ResponseImmunotherapyCessation Of LifeDesignHepatocyteGenetic TranscriptionGenetically Engineered Mouse
Grant awards (18)
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS$630,404
R01 · FY2025 · CA
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS$598,885
R01 · FY2024 · CA
Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC$589,164
R01 · FY2024 · CA
Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma$367,259
R37 · FY2024 · CA · contact PI
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS$617,796
R01 · FY2023 · CA
Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC$607,771
R01 · FY2023 · CA
Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma$378,856
R37 · FY2023 · CA · contact PI
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS$253,500
R01 · FY2023 · CA
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS$617,796
R01 · FY2022 · CA
Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC$607,766
R01 · FY2022 · CA
Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma$387,731
R37 · FY2022 · CA · contact PI
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS$631,336
R01 · FY2021 · CA
Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC$620,173
R01 · FY2021 · CA
Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma$387,731
R37 · FY2021 · CA · contact PI
Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC$634,298
R01 · FY2020 · CA
Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma$436,886
R37 · FY2020 · CA · contact PI
Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma$376,098
R37 · FY2019 · CA · contact PI
Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma$387,731
R37 · FY2018 · CA · contact PI